默沙东宣布，其药物Keytruda®（帕博利珠单抗）联合Padcev®（enfortumab vedotin-ejfv）用于治疗顺铂不适切的可切除肌层浸润性膀胱癌成人患者的围手术期治疗方案，已获得欧洲药品管理局人用药品委员会（CHMP）的积极意见。这一进展为治疗方案在欧洲的最终获批铺平了道路，有望为特定膀胱癌患者群体提供一种重要的新治疗选择。
默沙东宣布，其药物Keytruda®（帕博利珠单抗）联合Padcev®（enfortumab vedotin-ejfv）用于治疗顺铂不适切的可切除肌层浸润性膀胱癌成人患者的围手术期治疗方案，已获得欧洲药品管理局人用药品委员会（CHMP）的积极意见。这一进展为治疗方案在欧洲的最终获批铺平了道路，有望为特定膀胱癌患者群体提供一种重要的新治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.